---
title: "FDA Issues Temporary Policies to Protect Newborn Access to Starter Parenteral Nutrition"
id: "fda-news-releases-0-fda-takes-steps-to-maintain-newborn-access-to-life-saving-starter-nutrition"
canonical_url: "https://medichelpline.com/clinical-feed/fda-news-releases-0-fda-takes-steps-to-maintain-newborn-access-to-life-saving-starter-nutrition"
content_type: "clinical_feed_article"
specialty: "Pediatrics"
source_name: "FDA News Releases"
source_url: "http://www.fda.gov/news-events/press-announcements/fda-takes-steps-maintain-newborn-access-life-saving-starter-nutrition-products"
published_at: "2026-09-04T20:18:49.000Z"
evidence_level: "Agency Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# FDA Issues Temporary Policies to Protect Newborn Access to Starter Parenteral Nutrition
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/fda-news-releases-0-fda-takes-steps-to-maintain-newborn-access-to-life-saving-starter-nutrition
- **Specialty:** [Pediatrics](https://medichelpline.com/clinical-feed/pediatrics.md)
- **Primary Source:** FDA News Releases
- **Source URL:** [Original Journal Publication](http://www.fda.gov/news-events/press-announcements/fda-takes-steps-maintain-newborn-access-life-saving-starter-nutrition-products)
- **Published At:** 2026-09-04T20:18:49.000Z
- **Evidence Rating:** Agency Feed
## Executive GIST (TL;DR)
- The FDA announced immediate actions to address a potential supply gap in **neonatal starter parenteral nutrition (PN)** after children's hospitals reported concerns about continued access. - The concerns followed discontinuation of certain standardized neonatal starter PN products produced by two outsourcing facilities that are permanently closing. - The agency issued an immediately-in-effect guidance, Temporary Policies for Compounding Certain Starter Parenteral Nutrition Drug Products for Neonates, outlining temporary regulatory and enforcement priorities. - The guidance covers compounding by state-licensed pharmacies, federal facilities and outsourcing facilities under **sections 503A and 503B** of the Federal Food, Drug, and Cosmetic Act. - FDA leadership emphasized use of regulatory tools to prevent supply chain gaps affecting vulnerable patients; Acting FDA Commissioner Kyle Diamantas and Michael Davis, M.D., Ph.D., Acting CDER Center Director, are quoted in the release. - The temporary policies are intended to help hospitals maintain access to life-saving starter PN while longer-term solutions are pursued. - The FDA stated it will continue to monitor supply needs and consider additional actions if the situation changes. - Contact points for media and consumers were provided and the content is current as of September 4, 2026.
## Clinical Analysis & Structured Key Points
FDA Takes Steps to Maintain Newborn Access to Life-Saving Starter Nutrition Products | FDA Skip to main content Skip to FDA Search Skip to in this section menu Skip to footer links Home News & Events FDA Newsroom Press Announcements FDA Takes Steps to Maintain Newborn Access to Life-Saving Starter Nutrition Products Press Announcements In this section More Press Announcements For Immediate Release: September 04, 2026 The U.S. Food and Drug Administration today announced it is taking action, consistent with the Trump administration’s commitment to protecting vulnerable patients and maintaining access to critical medical products, to help address a potential supply gap of neonatal starter parenteral nutrition (PN). These products provide essential nutrients through an IV to premature and critically ill newborns who cannot receive nutrition by mouth or through a feeding tube. The FDA became aware of the potential supply gap after children’s hospitals raised concerns about continued access to neonatal starter parenteral nutrition. The concerns were based on the discontinuation of certain standardized neonatal starter PN products made by two outsourcing facilities that are permanently shutting down. “The FDA is committed to deploying every regulatory tool available to prevent critical supply chain gaps from threatening patient care,” said Acting FDA Commissioner Kyle Diamantas, J.D. “We are working closely with healthcare providers and industry partners to help ensure that vulnerable populations continue to have access to the care they need.” In response, the FDA assessed the situation and identified ways to help prevent a disruption in supply. As part of that effort, the agency is issuing an immediately-in-effect guidance, Temporary Policies for Compounding Certain Starter Parenteral Nutrition Drug Products for Neonates , describing the agency’s temporary regulatory and enforcement priorities regarding certain compounded starter parenteral nutrition drug products. The guidance is intended to help address potential supply gaps and support hospitals in continuing to access critical nutrition drug products while longer-term solutions are identified. “Starter parenteral nutrition is especially important for premature and critically ill newborns who need nutrition soon after birth,” said Michael Davis, M.D., Ph.D., Acting Center Director of FDA’s Center for Drug Evaluation and Research . “These temporary policies are intended to help hospitals maintain access to this life-saving nutrition during this transition.” The guidance describes regulatory and enforcement priorities for certain state-licensed pharmacies, federal facilities and outsourcing facilities that compound specified parenteral drugs under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. The FDA will continue to monitor current and expected supply needs and assess if additional action is needed as the situation develops. Media: FDA Request for Comment 202-690-6343 Consumer: 888-INFO-FDA ### Boilerplate The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, radiation-emitting electronic products, and for regulating tobacco products. Content current as of: 09/04/2026 Regulated Product(s) Drugs Follow FDA Follow @US_FDA on X Follow FDA on Facebook Follow @FDAMedia on X Feedback Back to Top
## Related Clinical Research

- [Strategies to Improve Access to HIV Services for Children in Malawi: Study Protocol](https://medichelpline.com/clinical-feed/plos-one-23-investigating-strategies-to-enhance-access-to-hiv-services-among-children-in.md)
- [Adolescent handgrip strength trends and reference values in Korea from KNHANES (2014–2022)](https://medichelpline.com/clinical-feed/plos-one-19-temporal-changes-and-reference-values-for-adolescent-handgrip-strength-in-the.md)
- [Reanalysis of Prenatal Acetaminophen and Neurodevelopmental Disorders Using Bias-Correction Methods](https://medichelpline.com/clinical-feed/medrxiv-0-testing-claimed-associations-of-prenatal-acetaminophen-with-neurodevelopmental.md)
- [Genetics of Childhood Eating Behaviors and Their Contribution to Obesity Risk](https://medichelpline.com/clinical-feed/medrxiv-8-genetic-and-behavioural-architecture-of-childhood-eating-behaviour-and-links-to.md)
- [Mother‑Child AI Agent (MoChiAgent) predicts maternal and infant outcomes from longitudinal EHRs](https://medichelpline.com/clinical-feed/nature-0-prediction-of-maternal-and-infant-outcomes-from-longitudinal-electronic-health.md)

## Navigation
- [← Back to Pediatrics Feed](https://medichelpline.com/clinical-feed/pediatrics.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.